Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
Mahon
François-Xavier
FX
Molimard
Mathieu
M
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001549:Benzamides; D020732:Cytogenetic Analysis; D016903:Drug Monitoring; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D015465:Leukemia, Myeloid, Accelerated Phase; D015466:Leukemia, Myeloid, Chronic-Phase; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D018570:Risk Assessment
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl